• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国的宫颈癌筛查

Cervical cancer screening in France.

作者信息

Schaffer P, Sancho-Garnier H, Fender M, Dellenbach P, Carbillet J P, Monnet E, Gauthier G P, Garnier A

机构信息

Programme EVE, Strasbourg, France.

出版信息

Eur J Cancer. 2000 Nov;36(17):2215-20. doi: 10.1016/s0959-8049(00)00312-9.

DOI:10.1016/s0959-8049(00)00312-9
PMID:11072207
Abstract

In France, as in other European countries the incidence and mortality rates of carcinoma of the cervix uteri indicate a clear decrease in invasive cancers. Opportunistic screening has spread and, presently, approximately 60% of the female population undergo a regular cytological test. This rate increases up to 80% in the younger age groups and decreases to 20% after the age of 60 years. In 1990, intervention procedures were defined at a consensus conference; the major recommendations were to screen all women exclusively by cervical smears, for ages 25-65 years over a 3-year period. Guidelines on the quality control of cervical smear taking and reading were published by the national agency of evaluation of health intervention (ANAES). Since 1990, four population-based, organised pilot programmes, have been implemented in Isère. Doubs, Bas-Rhin and Martinique. These programmes evaluate the participation rate (from approximately 20-80% depending upon the age and the geographical area), the rate of abnormal tests (0.2-3%), according to the laboratories, the cancer detection rate (0.04%-0.15%) and some other quality indicators. Recently (November 1998) a law was passed stipulating that the screening test will be free of charge when performed in agreement with the national recommendations. A specific organisation for cytological quality control will be implemented. An effort to better identify and to include the screening process the women in the population who are not yet participating has to be made.

摘要

在法国,与其他欧洲国家一样,子宫颈癌的发病率和死亡率表明浸润性癌症明显减少。机会性筛查已经普及,目前约60%的女性人口定期进行细胞学检查。这一比例在较年轻年龄组中升至80%,在60岁以后降至20%。1990年,在一次共识会议上确定了干预程序;主要建议是在25至65岁的女性中,每3年仅通过宫颈涂片进行筛查。国家卫生干预评估机构(ANAES)发布了宫颈涂片采集和判读质量控制指南。自1990年以来,在伊泽尔、杜省、下莱茵省和马提尼克岛实施了四项基于人群的有组织的试点项目。这些项目评估参与率(根据年龄和地理区域,从约20%至80%不等)、根据实验室情况的异常检查率(0.2%至3%)、癌症检出率(0.04%至0.15%)以及其他一些质量指标。最近(1998年11月)通过了一项法律,规定按照国家建议进行筛查检测将免费。将实施一个专门的细胞学质量控制组织。必须努力更好地识别并将尚未参与筛查过程的女性纳入人群筛查。

相似文献

1
Cervical cancer screening in France.法国的宫颈癌筛查
Eur J Cancer. 2000 Nov;36(17):2215-20. doi: 10.1016/s0959-8049(00)00312-9.
2
[Organized cervical cancer screening for underpriviledged women].为贫困妇女开展的宫颈癌筛查组织工作
Bull Cancer. 2007 May;94(5):461-7.
3
[Cervical cancer screening in the Bas-Rhin. Evaluation of four and a half years of the EVE campaign].[下莱茵省的宫颈癌筛查。EVE项目四年半评估]
Sante Publique. 2000 May;12 Spec No:11-20.
4
Cervical cancer screening in Denmark.丹麦的宫颈癌筛查
Eur J Cancer. 2000 Nov;36(17):2198-204. doi: 10.1016/s0959-8049(00)00309-9.
5
Cervical cancer screening in the Netherlands.荷兰的宫颈癌筛查
Eur J Cancer. 2000 Nov;36(17):2244-6. doi: 10.1016/s0959-8049(00)00317-8.
6
Population-based organized cervical cancer screening pilot program in France.法国基于人群的有组织宫颈癌筛查试点项目。
Eur J Cancer Prev. 2018 Sep;27(5):486-492. doi: 10.1097/CEJ.0000000000000365.
7
Cervical cancer screening in England.英格兰的宫颈癌筛查
Eur J Cancer. 2000 Nov;36(17):2205-8. doi: 10.1016/s0959-8049(00)00310-5.
8
[EVE, a regional campaign for the screening of cervical cancer. Organization, 7-years results and perspectives].[EVE,一项宫颈癌筛查的区域运动。组织、7年成果及展望]
Presse Med. 2003 Oct 11;32(33):1545-51.
9
Cervical cancer screening in Austria.奥地利的宫颈癌筛查
Eur J Cancer. 2000 Nov;36(17):2189-90. doi: 10.1016/s0959-8049(00)00322-1.
10
[Cervical cancer screening campaign in Doubs: evaluation of the first three years of the pilot program].
Sante Publique. 2000 May;12 Spec No:37-43.

引用本文的文献

1
Prevalence and Description of High-Grade Intraepithelial Lesions of Cervical Mucosa Cells in a Screening Programme for Cervical Cancer in Isère, France.法国伊泽尔省宫颈癌筛查计划中宫颈黏膜细胞高级别上皮内病变的流行情况和描述。
Cancer Med. 2024 Oct;13(19):e70259. doi: 10.1002/cam4.70259.
2
Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe.在瓜德罗普岛的宫颈癌中,除 16 型或 18 型外,HPV 频繁发生高危型合并感染。
BMC Cancer. 2021 Mar 16;21(1):281. doi: 10.1186/s12885-021-07940-3.
3
Challenges in the Prevention of Cervical Cancer in Romania.
罗马尼亚宫颈癌防治面临的挑战。
Int J Environ Res Public Health. 2021 Feb 10;18(4):1721. doi: 10.3390/ijerph18041721.
4
General practitioners who never perform Pap smear: the medical offer and the socio-economic context around their office could limit their involvement in cervical cancer screening.从未进行巴氏涂片检查的全科医生:医疗服务提供情况以及其诊所周边的社会经济环境可能会限制他们参与宫颈癌筛查。
BMC Fam Pract. 2019 Aug 15;20(1):114. doi: 10.1186/s12875-019-1004-x.
5
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.欧洲的宫颈癌筛查项目:向 HPV 疫苗接种和基于人群的 HPV 检测的转变。
Viruses. 2018 Dec 19;10(12):729. doi: 10.3390/v10120729.
6
The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.波兰有组织的宫颈癌筛查计划的实施:对欧洲指南依从性的分析。
BMC Cancer. 2015 Apr 14;15:279. doi: 10.1186/s12885-015-1242-9.
7
Evidence for cervical cancer mortality with screening program in Taiwan, 1981-2010: age-period-cohort model.台湾地区 1981-2010 年宫颈癌死亡率的筛查项目证据:年龄-时期-队列模型。
BMC Public Health. 2013 Jan 8;13:13. doi: 10.1186/1471-2458-13-13.
8
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.用于评估宫颈癌疫苗的通用成本效益模型。
Int J Public Health. 2011 Apr;56(2):153-62. doi: 10.1007/s00038-010-0216-6. Epub 2010 Nov 26.
9
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.在公共资助的医疗保健系统中,人乳头瘤病毒 DNA 检测与巴氏涂片在宫颈癌筛查中的成本效益分析。
Br J Cancer. 2010 Dec 7;103(12):1773-82. doi: 10.1038/sj.bjc.6605974. Epub 2010 Nov 23.
10
Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.端粒酶活性作为印度宫颈上皮内瘤变和宫颈癌女性患者的肿瘤标志物
Mol Diagn Ther. 2007;11(3):193-201. doi: 10.1007/BF03256241.